Neurocrine Biosciences (NBIX) Capital Expenditures (QoQ) (2010 - 2026)
Neurocrine Biosciences (NBIX) Capital Expenditures (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.29% |
| Mar 31, 2026 | 158.33% |
| Dec 31, 2025 | -106.96% |
| Sep 30, 2025 | 492.05% |
| Jun 30, 2025 | -182.24% |
| Mar 31, 2025 | -71.39% |
| Dec 31, 2024 | 1,596.00% |
| Sep 30, 2024 | 68.35% |
| Jun 30, 2024 | -170.54% |
| Mar 31, 2024 | 600.00% |
| Dec 31, 2023 | 1,500.00% |
| Sep 30, 2023 | -50.00% |
| Jun 30, 2023 | -66.67% |
| Mar 31, 2023 | 104.29% |
| Dec 31, 2022 | -201.45% |
| Sep 30, 2022 | 826.32% |
| Jun 30, 2022 | -167.86% |
| Mar 31, 2022 | -68.54% |
| Dec 31, 2021 | -27.64% |
| Sep 30, 2021 | 485.71% |